US Patent

US9248199 — 1:1 adducts of sickle hemoglobin

Method of Use · Assigned to Global Blood Therapeutics Inc · Expires 2034-01-29 · 8y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects 1:1 adducts of sickle hemoglobin and a compound of formula (I), suitable as modulators of HbS for treating disorders mediated by hemoglobin.

USPTO Abstract

Provide herein are 1:1 adducts of sickle hemoglobin (HbS) and a compound of formula (I), as defined herein, suitable as modulators of HbS, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Drugs covered by this patent

Oxbryta (voxelotor) · Global Blood Theraps

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2676`	—	Oxbryta
`U-2676`	—	Oxbryta
`U-2676`	—	Oxbryta

Patent Metadata

Patent number: US9248199
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-29
Drug substance claim: No
Drug product claim: No
Assignee: Global Blood Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.